Dolutegravir for the treatment of HIV-2 infection

Faria, 2012, Phylo-geographical footprint of colonial history in the global dispersal of HIV-2 group A, J. Gen. Virol., 93, 889, 10.1099/vir.0.038638-0 Gottlieb, 2002, Equal plasma viral loads predict a similar rate of CD4+ T cell decline in HIV type 1- and HIV-2-infected individuals from Senegal, West Africa, J. Infect. Dis., 185, 905, 10.1086/339295 Damond, 2011, An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHIEV2E quality control study, J. Clin. Microbiol., 49, 3491, 10.1128/JCM.02389-10 Benard, 2011, Immuno-virological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E collaboration study group, Clin. Infect. Dis., 52, 1257, 10.1093/cid/cir123 Raugi, 2013, Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy, Antimicrob. Agents Chemother., 57, 2751, 10.1128/AAC.00405-13 Smith, 2012, Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens, PLoS One, 9, e45372, 10.1371/journal.pone.0045372 Cavaco-Silva, 2014, HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen, PLoS One, 9, e92747, 10.1371/journal.pone.0092747 Fernandez-Montero, 2014, Dolutegravir, abacavir and lamivudine as HIV therapy, Expert Opin. Pharmacother., 15, 1051, 10.1517/14656566.2014.913023 Charpentier, 2013, HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe, Clin. Infect. Dis., 56, 1654, 10.1093/cid/cit104 Menéndez-Arias, 2014, Antiretroviral therapy and drug resistance in HIV type 2 infection, Antiviral Res., 102, 70, 10.1016/j.antiviral.2013.12.001 Treviño, 2011, Drug resistance mutations in patients infected with HIV-2 living in Spain, J. Antimicrob. Chemother., 66, 1484, 10.1093/jac/dkr164 Rodés, 2007, Quantitative detection of plasma HIV type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1), J. Clin. Microbiol., 45, 88, 10.1128/JCM.01613-06 De Mendoza, 2014, HIV-2 and HTLV-1 infections in Spain, a non-endemic region, AIDS Rev., 16, 152 Clavel, 1986, Isolation of a new human retrovirus from West African patients with AIDS, Science, 233, 343, 10.1126/science.2425430 Andreatta, 2013, HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro, J. Acquir. Immune Defic. Syndr., 62, 367, 10.1097/QAI.0b013e31827b55f1 Salgado, 2009, Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity, J. Clin. Virol., 46, 173, 10.1016/j.jcv.2009.06.020 Treviño, 2013, Drug resistance mutations in HIV-2 patients failing raltegravir-extent of cross-resistance to dolutegravir, Antivir. Ther., 18, A105